Blog · Safety First
Ibogaine is not risk-free. The clearest concern is cardiac: it can prolong the QT interval, interacts with hERG potassium channels, and has been associated with serious arrhythmias and deaths — especially in poorly screened or poorly monitored settings. That does not mean it should be dismissed or hyped. It means any serious discussion has to start with safety, screening, medical monitoring, and the fact that the evidence is still early.
Ibogaine is a psychoactive compound found in the root bark of Tabernanthe iboga, a plant used traditionally in Central Africa. In modern settings it has attracted attention because of reports that it may interrupt substance-use patterns, especially opioid dependence. There are observational studies, case series, and growing public interest — but the clinical evidence base remains limited compared with established medical treatments.
The safety profile is the central issue. Ibogaine and its metabolite noribogaine can affect cardiac repolarisation — the electrical reset cycle of the heart. QT prolongation is measurable on an ECG; when the QT interval becomes too long, the risk of dangerous rhythm disturbances increases, including torsades de pointes, which can be life-threatening. The hERG channel matters because it is one of the key cardiac potassium channels involved in repolarisation, and many QT-prolonging drugs act through it. The cardiac concern is not theoretical — it is the main reason responsible clinicians insist on ECG screening, electrolyte checks, medication review, and continuous monitoring during administration.
The Global Ibogaine Therapy Alliance (GITA) published clinical guidelines intended to reduce risk in ibogaine settings. They are not a guarantee of safety, but they point to the right seriousness: screen for cardiac disease, check the QT interval, review medications and substances, assess liver function, correct electrolyte abnormalities, monitor during and after dosing, and require trained staff, emergency readiness, and exclusion criteria. For Ashta this is non-negotiable. Ibogaine is not a retreat novelty or a casual "plant-medicine add-on"; if it is ever studied in relation to our extended-state work, it must be treated as a high-safety-threshold intervention requiring qualified medical oversight, lawful operation, proper screening, and emergency protocols.
The public conversation changed in 2024 when Nature Medicine published a Stanford-linked study on magnesium-ibogaine in military veterans with traumatic brain injury, reporting improvements in disability, PTSD, depression and anxiety after treatment in a small group, in a medically supervised setting. The honest reading is: promising, not settled. The study was small and early — not a large, blinded, placebo-controlled trial. It does not prove broad safety or efficacy, and it does not remove the cardiac risk. Texas also moved into the conversation with Senate Bill 2308, connected to funding ibogaine research; but legislation is not evidence — it can fund evidence, it cannot substitute for it.
For Ashta, the research question is not "does ibogaine transform people?" — too vague. The better questions are specific and measurable: what happens to tracked goals, voice markers, HRV, sleep, self-report and social functioning after an ibogaine experience; which changes persist after weeks or months; which participants should be excluded for safety; what adverse events occur, and how are they reported? And nulls must be published: if tracked goals do not change despite a powerful experience, that matters; if risks outweigh benefits in a given context, that matters most. Ashta's stance is safety first, claims second, evidence always.
